Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

Abstract : IntroductionThe main objective of this work was to assess the maintenance of effectiveness of subcutaneous tocilizumab 6months after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis(RA) in a real-world setting. Secondary objectives aimed to describe the characteristics of patients and disease, the effectiveness at 12months after switching, the therapeutic maintenance, and to search for predictive factors of switching.MethodsWe analyzed all the RA patients of the shared medical file RIC Nord de France, treated with tocilizumab, switching or not from intravenous to subcutaneous tocilizumab, between April 2015 and January 2016. The primary effectiveness endpoint was the proportion of patients remaining in their DAS28-ESR category remission/low disease activity (LDA) or moving to an inferior DAS28-ESR category at 6months. Since RoSwitch was an observational study, without randomization, a propensity score was built in a sensitivity analysis to balance on RA and patients' characteristics at inclusion between switching and no-switching groups.ResultsAn improvement of initial DAS28-ESR category or maintenance in DAS28-ESR remission/LDA at 6months was shown in 203 of the 285 patients with an evaluation for the primary criterion (71.2%, 95% CI [65.6-76.4%]) without differences between groups (73.3%, 95% CI [63.0-82.1%] vs. 70.3%, 95% CI [63.3-76.6%]). The RoSwitch study showed the maintenance of effectiveness at 6 and 12months. Similar therapeutic maintenance rates were observed for switch and no-switch patients. No clinical factor was associated with the switch in patients in remission/LDA at inclusion.ConclusionsThe RoSwitch study showed the maintenance of effectiveness at 6months in RA patients switching from intravenous (IV) to subcutaneous (SC) tocilizumab.FundingRoche SAS and Chugai Pharma France.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03606083
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : vendredi 11 mars 2022 - 15:12:52
Dernière modification le : mercredi 7 septembre 2022 - 16:22:25

Lien texte intégral

Identifiants

Collections

Citation

Jean Darloy, Nicolas Segaud, Jean-Hugues Salmon, Jean-Paul Eschard, Vincent Goeb, et al.. Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study. Rheumatology and Therapy, Springer, 2019, 6 (1), pp.61-75. ⟨10.1007/s40744-018-0138-y⟩. ⟨hal-03606083⟩

Partager

Métriques

Consultations de la notice

5